Income Tax Expense (Benefit)
Effective Income Tax Rate (EITR)
Components of Deferred Tax Assets and Liabilities
Deferred Tax Assets and Liabilities, Classification
Adjustments to Financial Statements: Removal of Deferred Taxes
Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)
Adjusted Net Profit Margin
Adjusted Total Asset Turnover
Adjusted Financial Leverage
Adjusted Return on Equity (ROE)
Adjusted Return on Assets (ROA)

Gilead Sciences Inc., income tax expense (benefit), continuing operations

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Federal	1,495)	1,781)	2,539)	1,776)	1,450)
State	39)	80)	32)	228)	198)
Foreign	519)	381)	232)	185)	155)
Current	2,053)	2,242)	2,803)	2,189)	1,803)
Federal	(1,562)	(1,126)	(1,502)	(250)	(164)
State	(386)	170)	(154)	185)	(97)
Foreign	106)	(39)	101)	(47)	38)
Deferred	(1,842)	(995)	(1,555)	(112)	(223)
Income tax expense	211)	1,247)	1,248)	2,077)	1,580)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
Current	Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.	Gilead Sciences Inc. current decreased from 2022 to 2023 and from 2023 to 2024.
Deferred	Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.	Gilead Sciences Inc. deferred increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Income tax expense	Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.	Gilead Sciences Inc. income tax expense decreased from 2022 to 2023 and from 2023 to 2024.

Gilead Sciences Inc., effective income tax rate (EITR) reconciliation

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Federal statutory tax rate	21.00%	21.00%	21.00%	21.00%	21.00%
State taxes, net of federal benefit	-43.60%	2.30%	-2.00%	2.50%	4.20%
Foreign earnings at different rates	10.90%	-0.20%	-0.60%	-0.30%	-10.00%
Research and other credits	-31.60%	-4.30%	-2.70%	-1.60%	-6.90%
US tax on foreign earnings	12.10%	1.00%	2.70%	1.10%	7.20%
Foreign-derived intangible income deduction	-19.30%	-2.10%	-3.80%	-1.60%	-8.00%
Tax examinations	-33.70%	-4.70%	-0.20%	-0.70%	-10.20%
Acquired IPR&D & related charges	117.30%	1.30%	1.40%	0.00%	56.20%
Changes in valuation allowance	15.60%	0.90%	1.20%	1.50%	6.70%
Non-taxable unrealized loss on investment	6.80%	0.20%	0.70%	1.80%	23.00%
Legal entity restructuring	-52.60%	0.00%	0.00%	0.00%	0.00%
Other	27.60%	2.80%	3.80%	1.40%	11.50%
Effective tax rate	30.50%	18.20%	21.50%	25.10%	94.70%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
Effective tax rate	Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.	Gilead Sciences Inc. effective tax rate decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Gilead Sciences Inc., components of deferred tax assets and liabilities

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net operating loss carryforwards	288)	417)	430)	413)	587)
Stock-based compensation	84)	94)	95)	117)	113)
Reserves and accruals not currently deductible	685)	644)	645)	700)	444)
Excess of tax basis over book basis of intangible assets	910)	1,041)	1,067)	1,157)	1,177)
Upfront and milestone payments	1,312)	1,271)	1,298)	1,310)	1,144)
Research and other credit carryforwards	428)	283)	233)	249)	219)
Equity investments	237)	221)	196)	117)	116)
Liability related to future royalties	287)	296)	278)	274)	247)
Capitalized R&D expenditures	2,173)	1,623)	784)	—)	—)
Capital losses	590)	17)	—)	—)	—)
Other, net	213)	303)	263)	292)	311)
Deferred tax assets before valuation allowance	7,207)	6,210)	5,289)	4,629)	4,358)
Valuation allowance	(1,217)	(663)	(599)	(520)	(398)
Deferred tax assets	5,990)	5,547)	4,690)	4,109)	3,960)
Property, plant and equipment	(276)	(274)	(234)	(227)	(202)
Excess of book basis over tax basis of intangible assets	(3,836)	(5,481)	(5,728)	(6,719)	(6,168)
Other	(224)	(184)	(160)	(180)	(202)
Deferred tax liabilities	(4,336)	(5,939)	(6,122)	(7,126)	(6,572)
Net deferred tax assets (liabilities)	1,654)	(392)	(1,432)	(3,017)	(2,612)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
Deferred tax assets before valuation allowance	Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.	Gilead Sciences Inc. deferred tax assets before valuation allowance increased from 2022 to 2023 and from 2023 to 2024.
Deferred tax assets	Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.	Gilead Sciences Inc. deferred tax assets increased from 2022 to 2023 and from 2023 to 2024.
Net deferred tax assets (liabilities)	Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.	Gilead Sciences Inc. net deferred tax assets (liabilities) increased from 2022 to 2023 and from 2023 to 2024.

Gilead Sciences Inc., deferred tax assets and liabilities, classification

US$ in millions

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
	Deferred tax asset	2,378)	1,196)	1,241)	1,339)	1,302)
	Deferred tax liability	724)	1,588)	2,673)	4,356)	3,914)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
Deferred tax asset	Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.	Gilead Sciences Inc. deferred tax asset decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Deferred tax liability	Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.	Gilead Sciences Inc. deferred tax liability decreased from 2022 to 2023 and from 2023 to 2024.

Gilead Sciences Inc., adjustments to financial statements

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Adjustment to Total Assets
Total assets (as reported)	58,995)	62,125)	63,171)	67,952)	68,407)
Less: Noncurrent deferred tax assets, net	2,378)	1,196)	1,241)	1,339)	1,302)
Total assets (adjusted)	56,617)	60,929)	61,930)	66,613)	67,105)
Adjustment to Total Liabilities
Total liabilities (as reported)	39,749)	39,376)	41,962)	46,888)	50,186)
Less: Noncurrent deferred tax liabilities, net	724)	1,588)	2,673)	4,356)	3,914)
Total liabilities (adjusted)	39,025)	37,788)	39,289)	42,532)	46,272)
Adjustment to Total Gilead Stockholders’ Equity
Total Gilead stockholders’ equity (as reported)	19,330)	22,833)	21,240)	21,069)	18,202)
Less: Net deferred tax assets (liabilities)	1,654)	(392)	(1,432)	(3,017)	(2,612)
Total Gilead stockholders’ equity (adjusted)	17,676)	23,225)	22,672)	24,086)	20,814)
Adjustment to Net Income Attributable To Gilead
Net income attributable to Gilead (as reported)	480)	5,665)	4,592)	6,225)	123)
Add: Deferred income tax expense (benefit)	(1,842)	(995)	(1,555)	(112)	(223)
Net income attributable to Gilead (adjusted)	(1,362)	4,670)	3,037)	6,113)	(100)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Gilead Sciences Inc., Financial Data: Reported vs. Adjusted

Download chart

Gilead Sciences Inc., adjusted financial ratios

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Profit Margin
Reported net profit margin	1.68%	21.03%	17.02%	23.05%	0.51%
Adjusted net profit margin	-4.76%	17.34%	11.26%	22.63%	-0.41%
Total Asset Turnover
Reported total asset turnover	0.48	0.43	0.43	0.40	0.36
Adjusted total asset turnover	0.51	0.44	0.44	0.41	0.36
Financial Leverage
Reported financial leverage	3.05	2.72	2.97	3.23	3.76
Adjusted financial leverage	3.20	2.62	2.73	2.77	3.22
Return on Equity (ROE)
Reported ROE	2.48%	24.81%	21.62%	29.55%	0.68%
Adjusted ROE	-7.71%	20.11%	13.40%	25.38%	-0.48%
Return on Assets (ROA)
Reported ROA	0.81%	9.12%	7.27%	9.16%	0.18%
Adjusted ROA	-2.41%	7.66%	4.90%	9.18%	-0.15%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Financial ratio	Description	The company
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by total revenue.	Gilead Sciences Inc. adjusted net profit margin ratio improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Gilead Sciences Inc. adjusted total asset turnover ratio improved from 2022 to 2023 and from 2023 to 2024.
Adjusted financial leverage	A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity. Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.	Gilead Sciences Inc. adjusted financial leverage ratio decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by adjusted shareholders’ equity.	Gilead Sciences Inc. adjusted ROE improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by adjusted total assets.	Gilead Sciences Inc. adjusted ROA improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

Gilead Sciences Inc., Financial Ratios: Reported vs. Adjusted

Download chart

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead	480)	5,665)	4,592)	6,225)	123)
Product sales	28,610)	26,934)	26,982)	27,008)	24,355)
Profitability Ratio
Net profit margin¹	1.68%	21.03%	17.02%	23.05%	0.51%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead	(1,362)	4,670)	3,037)	6,113)	(100)
Product sales	28,610)	26,934)	26,982)	27,008)	24,355)
Profitability Ratio
Adjusted net profit margin²	-4.76%	17.34%	11.26%	22.63%	-0.41%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ Net profit margin = 100 × Net income attributable to Gilead ÷ Product sales
= 100 × 480 ÷ 28,610 = 1.68%

² Adjusted net profit margin = 100 × Adjusted net income attributable to Gilead ÷ Product sales
= 100 × -1,362 ÷ 28,610 = -4.76%

Download chart

Profitability ratio	Description	The company
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by total revenue.	Gilead Sciences Inc. adjusted net profit margin ratio improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Product sales	28,610)	26,934)	26,982)	27,008)	24,355)
Total assets	58,995)	62,125)	63,171)	67,952)	68,407)
Activity Ratio
Total asset turnover¹	0.48	0.43	0.43	0.40	0.36
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Product sales	28,610)	26,934)	26,982)	27,008)	24,355)
Adjusted total assets	56,617)	60,929)	61,930)	66,613)	67,105)
Activity Ratio
Adjusted total asset turnover²	0.51	0.44	0.44	0.41	0.36

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ Total asset turnover = Product sales ÷ Total assets
= 28,610 ÷ 58,995 = 0.48

² Adjusted total asset turnover = Product sales ÷ Adjusted total assets
= 28,610 ÷ 56,617 = 0.51

Download chart

Activity ratio	Description	The company
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Gilead Sciences Inc. adjusted total asset turnover ratio improved from 2022 to 2023 and from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Total assets	58,995)	62,125)	63,171)	67,952)	68,407)
Total Gilead stockholders’ equity	19,330)	22,833)	21,240)	21,069)	18,202)
Solvency Ratio
Financial leverage¹	3.05	2.72	2.97	3.23	3.76
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets	56,617)	60,929)	61,930)	66,613)	67,105)
Adjusted total Gilead stockholders’ equity	17,676)	23,225)	22,672)	24,086)	20,814)
Solvency Ratio
Adjusted financial leverage²	3.20	2.62	2.73	2.77	3.22

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= 58,995 ÷ 19,330 = 3.05

² Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Gilead stockholders’ equity
= 56,617 ÷ 17,676 = 3.20

Download chart

Solvency ratio	Description	The company
Adjusted financial leverage	A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity. Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.	Gilead Sciences Inc. adjusted financial leverage ratio decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead	480)	5,665)	4,592)	6,225)	123)
Total Gilead stockholders’ equity	19,330)	22,833)	21,240)	21,069)	18,202)
Profitability Ratio
ROE¹	2.48%	24.81%	21.62%	29.55%	0.68%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead	(1,362)	4,670)	3,037)	6,113)	(100)
Adjusted total Gilead stockholders’ equity	17,676)	23,225)	22,672)	24,086)	20,814)
Profitability Ratio
Adjusted ROE²	-7.71%	20.11%	13.40%	25.38%	-0.48%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ ROE = 100 × Net income attributable to Gilead ÷ Total Gilead stockholders’ equity
= 100 × 480 ÷ 19,330 = 2.48%

² Adjusted ROE = 100 × Adjusted net income attributable to Gilead ÷ Adjusted total Gilead stockholders’ equity
= 100 × -1,362 ÷ 17,676 = -7.71%

Download chart

Profitability ratio	Description	The company
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by adjusted shareholders’ equity.	Gilead Sciences Inc. adjusted ROE improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead	480)	5,665)	4,592)	6,225)	123)
Total assets	58,995)	62,125)	63,171)	67,952)	68,407)
Profitability Ratio
ROA¹	0.81%	9.12%	7.27%	9.16%	0.18%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead	(1,362)	4,670)	3,037)	6,113)	(100)
Adjusted total assets	56,617)	60,929)	61,930)	66,613)	67,105)
Profitability Ratio
Adjusted ROA²	-2.41%	7.66%	4.90%	9.18%	-0.15%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ ROA = 100 × Net income attributable to Gilead ÷ Total assets
= 100 × 480 ÷ 58,995 = 0.81%

² Adjusted ROA = 100 × Adjusted net income attributable to Gilead ÷ Adjusted total assets
= 100 × -1,362 ÷ 56,617 = -2.41%

Download chart

Profitability ratio	Description	The company
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by adjusted total assets.	Gilead Sciences Inc. adjusted ROA improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Income Taxes

Income Tax Expense (Benefit)

Effective Income Tax Rate (EITR)

Components of Deferred Tax Assets and Liabilities

Deferred Tax Assets and Liabilities, Classification

Adjustments to Financial Statements: Removal of Deferred Taxes

Gilead Sciences Inc., Financial Data: Reported vs. Adjusted

Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Gilead Sciences Inc., Financial Ratios: Reported vs. Adjusted

Adjusted Net Profit Margin

Adjusted Total Asset Turnover

Adjusted Financial Leverage

Adjusted Return on Equity (ROE)

Adjusted Return on Assets (ROA)